SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around the joke-based Solana token and its 19-month anniversary. The community is actively asking "What's UpDog?" and highlighting its listing on the Jupiter Strict List while encouraging others to load up on $SOL clips.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around positive sentiment and long-term holding, emphasizing the "WAGMITHON" and strong community support. The community is speculating about a potential CMC listing while highlighting the token's solid liquidity and cultural appeal within the $SOL ecosystem. Discussions also focus on the project's doxxed team and consistent growth.

CATULU | THE THREADED FAMILIAR  Catulu is like Tamagotchi for the Twitter age — except your pet lives on the timeline, and the more you play, the more everyone sees it.  Platform & Core Mechanics Platform: Twitter + Web3 (Solana) Core Loop: Tweeting = Feeding, Cleansing, Training Tokens: $CATULU (native currency of the ecosystem)   Level up your characters to unlock more avatar images , get into top ranks on leaderboard and earn LP rewards.

CATULU

CATULU is trending as community members highlight its availability on Phantom Wallet and anticipate potential listings. The conversation is fueled by bullish sentiment, with many users expressing excitement and urging others to buy. Discussions also include comparisons to other meme coins like UPDOG and PEPE.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is trending as community members highlight its potential within the Avalanche network, noting its fully diluted supply and predictions of significant influx of RWAs; the overall sentiment suggests a possible run. Some users point to Forbes coverage and increasing TVL as reasons for optimism, while others focus on tokenomics and compare it to other DeFi projects.

GME Ethereum

GME Ethereum is trending as the community anticipates a "God Candle" and a tweet from Roaring Kitty, potentially signaling a major surge. Discussions also revolve around JTR Crypto (JTRAMBO) and its recent market cap milestones, with community members emphasizing a "buy and hold" strategy. However, some users are raising concerns about the legitimacy of the project and its affiliation with GameStop.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci is trending as community members anticipate news regarding a potential partnership with Dallah Pharma and the related SFDA application for Multikine, an immunotherapy treatment. The community expresses optimism about Multikine's potential in the Saudi Arabian market, aligning with Saudi Vision 2030, but also discusses the company's history and possible future dilution. Chatter revolves around potential catalysts and speculation about a short squeeze.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions about stablecoin regulation and increasing adoption across various blockchains like Solana. Community members are actively discussing USDC's role in DeFi, cross-chain transfers, and partnerships with major players such as Visa. There's also conversation around potential competition from other stablecoins and real-world asset tokenization initiatives.

Green Satoshi Token

GSTSOL is gaining attention as traders discuss its potential for a significant breakout, with some pointing to technical indicators and increasing volume as bullish signals. The community is closely watching for a catalyst that could trigger a rally, while also considering factors like its low market cap and past performance. Sentiment is mixed, with some expressing frustration over previous price action and others remaining optimistic about future gains.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending as the company announced a convertible notes offering, leading to mixed reactions from the community; some view it as a strategic move for growth and AI expansion, while others worry about potential dilution. Discussions also revolve around the upcoming ACA subsidy extension and its potential impact on the stock, with some traders positioning for a longer-term bullish outlook in the healthcare sector.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending with community members expressing excitement and urging others to buy in, suggesting a possible surge in interest and momentum. The community is highlighting the project's potential, referencing breaking through resistance levels, and encouraging others to join before it's too late. Chatter also mentions potential collaboration with other meme tokens.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beyond Tesla: Why GM and Ford Heavy ETFs Could Be Safer Bets Now?

GM and Ford-focused ETFs like RPV, MADE, and COWZ may offer investors stability as Tesla faces a post-subsidy demand cliff.  

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

Why Free Cash Flow Drives Superior Stock Performance

Here's why companies with high free cash flow often demonstrate high quality.

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the Health and Human Services Department, led by Robert F. Kennedy Jr., plans to "drastically" cut federal funding for domestic HIV prevention.While cuts have not been finalized, the Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b?mod=Searchresults_pos1&amp;page=1&amp;mod=article_inline&amp;adobe_mc=MCMID%3D74537243080012175182679892959762943330%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1742440495&amp;_gl=1*1myqz7*_gcl_au*NTUzNDY5MDY4LjE3MzUyMTA0MzI.*_ga*MTg1Mzg3MjI1NS4xNzE4OTcyNDYz*_ga_K2H7B9JRSS*MTc0MjQ0MDIzNy4yNi4xLjE3NDI0NDA0OTMuNjAuMC4w">reported</a>, citing people familiar with the matter, that they could be announced soon as part of the Trump administration's broader budget reductions at the Centers for Disease Control and Prevention.Gilead, which has a portfolio of HIV prevention treatments such as Biktarvy and Descovy, risks a hit to revenues if the report turns out to be true.However, retail investors and Wall Street analysts remain largely unfazed for now.Retail sentiment for Gilead on Stocktwits climbed further into the 'extremely bullish' zone on Wednesday, with message volume up 57% following the news.&nbsp;<figure class="image"><img style="aspect-ratio:1318/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GILD_sentiment_and_message_volume_as_of_March_19_png_baa27803b8.webp" alt="GILD sentiment and message volume as of March 19.png" width="1318" height="302"><figcaption>GILD sentiment and message volume as of March 19. | source: Stocktwits</figcaption></figure>Observers on the platform cited Gilead's dominance in HIV treatments, growing oncology presence, and strong free cash flow as reasons to hold on to the stock.<stembedurl>https://stocktwits.com/Bitcoin333/message/608542775</stembedurl><stembedurl>https://stocktwits.com/skcots131313/message/608543583</stembedurl>According to The Fly, JPMorgan acknowledged that the WSJ report is "clearly not a positive" but says the potential cuts wouldn't impact access to PrEP (pre-exposure prophylaxis). The firm noted that the CDC doesn't reimburse PrEP drugs but funds research and education.&nbsp;The research firm remains bullish on Gilead's lenacapavir — a twice-yearly injectable HIV-1 capsid inhibitor — as a key growth driver and maintains an 'Overweight' rating on the stock.Oppenheimer sees Gilead's pullback as a reaction to uncertainty but doesn't view the funding concerns as a material risk. The firm estimates PrEP revenues account for just 8% of Gilead's total sales, with Medicaid representing an even smaller fraction.&nbsp;It expects early lenacapavir adoption mostly from private insurers and reiterated an 'Outperform' rating with a $132 price target.If approved by the Food and Drug Administration, Morgan Stanley reportedly estimates that lenacapavir could generate annual sales of over $6 billion by 2030.According to Koyfin data, Gilead stock currently trades at a 13.5x forward earnings multiple, compared to Eli Lilly's 36.1x and Amgen's 15.3x.Shares of Gilead are up 16% this year, outperforming the NASDAQ Biotechnology Index's 3% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Equity

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.


HP, Inc. (<a class="mention" data-mention="$HPQ" data-symbol-id="HPQ" href="https://stocktwits.com/symbol/HPQ" target="_blank">$HPQ</a>) shares fell sharply in Wednesday’s premarket session after the Palo Alto-based company announced fiscal year 2024 fourth-quarter results roughly in line with expectations and running quarter guidance that trailed, reflecting the ongoing weakness in the global PC industry.&nbsp;The manufacturer of personal computing, printing, 3D printing, and gaming products, said its fourth-quarter non-GAAP earnings per share came in at $0.93, within the guidance range of $0.89-$0.99 and in line with the consensus.Net revenue rose a modest 1.7% year-over-year (YoY) to $14.1 billion compared to the $13.99&nbsp;billion consensus estimate. Personal systems net revenue climbed 2% to $9.6 billion,&nbsp;representing around 68% of the total, and printing net revenue was up 1%.Estimates from Gartner&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gartner.com/en/newsroom/press-releases/2024-10-09-gartner-says-worldwide-pc-shipments-declined-1-percent-in-third-quarter-of-2024">showed</a> global PC shipments falling 1.3% YoY to 62.9 million units in the third quarter, with HP’s shipments seeing a marginal YoY drop.Enrique Lores, HP President and CEO, said, "We are pleased with our Q4 performance where we saw revenue growth for the second consecutive quarter, driven by steady progress in Personal Systems and Print."HP said it returned $1.2 billion to shareholders in the form of share repurchase and dividends.&nbsp;The company announced a 5% increase to its annual dividend. The board declared a $0.2894 quarterly dividend, payable on Jan. 2, 2025, to shareholders of record as of Dec. 11, 2024.Looking ahead, HP expects non-GAAP EPS of $0.70-$0.76 for the first quarter of the fiscal year 2025 and $3.45-$3.75 for the full year. Analysts, on average, expect the metrics to come in at $0.82 and $3.60, respectively.&nbsp;CFO Karen Parkhill said, “As we look ahead, we are well positioned to deliver solid growth across revenue, non-GAAP net earnings, EPS and free cash flow in FY25.”As of 8:30 a.m. ET in premarket trading, HP shares were trading down 8.26% at $35.87. The stock, though, has gained over 33% so far this year.<figure class="image"><a href="https://stocktwits.com/symbol/HPQ"><img style="aspect-ratio:630/131;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/hp_sentiment_df3a5935b3.png" alt="hp-sentiment.png" width="630" height="131"></a><figcaption>HP sentiment and message volume November 25, 2024, premarket as of 8:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, sentiment toward the stock flipped to ‘extremely bearish’ (5/100) from ‘extremely bullish,’&nbsp;marking a year-low. Meanwhile, message volume&nbsp;climbed further into the&nbsp;‘extremely high’&nbsp;(97/100) territory, the highest it has been this year.Rival Dell Technologies, Inc. ($DELL), despite the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dell-q3-2025-earnings-beat-estimates-revenue-trails/cJI0ul9RW3">post-earnings plunge,</a> was viewed more positively by retailers, given its exposure to artificial intelligence servers.&nbsp;For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rambus-initiated-at-outperform-at-baird/cJIWrizRgU">Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat</a>

Global PC shipments fell 1.3% YoY in Q3, according to Gartner.

HP Q4 Results Deflate Retail Mood: Stock Sinks Over 8% As In-Line Quarterly Results, Sub-par Guidance Worry Traders

HP reported low single-digit revenue growth for its personal systems as well as printing segments.

ZoomInfo Technologies, Inc. ($ZI), a B2B platform that offers a commercial search-engine for companies and businesses, reported third-quarter results that exceeded expectations and issued fairly in-line guidance for the fourth quarter and the full year.Vancouver, Washington-based ZoomInfo reported third-quarter non-GAAP earnings per share of $0.28, up from $0.26 earned a year-ago. The bottom-line result exceeded the consensus estimate of $0.22.Revenue, however, fell 3% year-over-year (YoY) to $303.6 million and yet surpassed the $299.36-million consensus estimate.Henry Schuck, ZoomInfo founder and CEO, said, "We continued our move up-market, fueled by ZoomInfo Copilot and Operations growth, and we delivered strong financial results while improving the quality of new customers that we are bringing in.""The entire company is more focused than ever on delighting both our new and existing users via robust product innovation and customer obsession."The company noted that net revenue retention was stable for the third consecutive quarter, as it grew its $100,000 and million-dollar customer cohorts yet again.&nbsp;Looking ahead, the company narrowed its full-year revenue guidance from $1.19 billion-$1.205 billion to $1.201 billion-$1.204 billion. It raised its non-GAAP EPS guidance from $0.86-$0.88 to $0.92-$0.93.&nbsp;Analysts, on average, expect revenue of $1.2 billion and non-GAAP EPS of $0.90.ZoomInfo guided to fourth-quarter revenue of $296 million-$299 million and non-GAAP EPS of $0.22-$0.23. This compares to the consensus estimates of $296.91 million and $0.23, respectively.Following the results, Mizuho raised the price target for the stock from $9 to $11 while maintaining a Neutral rating, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=ZI">reported.</a> The firm described the quarter as "healthy," and also noted that the management sees small business write-offs abating.&nbsp;The company was seeing traction with its artificial intelligence offerings and the CoPilot solution, especially with mid-market and enterprise segments, the firm added.Retailers on the Stocktwits platform were mixed about the stock. One of them said the company is struggling in one of the best macro environments in history.<stembedurl>https://stocktwits.com/ASAP17/message/592252559</stembedurl>Another termed the stock as a “catch-up play” and noted that the short interest was high.<stembedurl>https://stocktwits.com/Chickenstick1/message/592245466</stembedurl>In premarket trading as of 8:40 am ET, the stock was down a steep 12.84% to $11.40.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cava-reports-2024-q3-beat-lifts-guidance/cJ4jPR2ROH">CAVA Stock Soars As Tasty Q3 Results Earn Wall Street Cheers, But Retail Appetite Mixed</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

ZoomInfo Stock Plunges Despite Q3 Beat As Traders Fret Over Shrinking Revenue: Retail Remains Wary

ZoomInfo CEO Schuck said the company is focused on satisfying new and existing customers through product innovation and customer obsession.

Pacer Funds Trust - Pacer US Cash Cows 100 ETF

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

COWZ
Pacer Funds Trust - Pacer US Cash Cows 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest COWZ News

COWZ Pacer Funds Trust - Pacer US Cash Cows 100 ETF